RhumbLine Advisers’s Novavax NVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.93M Buy
204,665
+15,065
+8% +$135K ﹤0.01% 1956
2026
Q1
$1.54M Sell
189,600
-155
-0.1% -$1.41K ﹤0.01% 1993
2025
Q4
$1.28M Sell
189,755
-32,320
-15% -$244K ﹤0.01% 2103
2025
Q3
$1.93M Sell
222,075
-9,842
-4% -$76.6K ﹤0.01% 1931
2025
Q2
$1.46M Buy
231,917
+16,504
+8% +$109K ﹤0.01% 2057
2025
Q1
$1.38M Buy
215,413
+6,949
+3% +$57.4K ﹤0.01% 2017
2024
Q4
$1.68M Buy
208,464
+13,024
+7% +$126K ﹤0.01% 1982
2024
Q3
$2.47M Sell
195,440
-4,469
-2% -$57.7K ﹤0.01% 1797
2024
Q2
$2.53M Buy
199,909
+56,324
+39% +$567K ﹤0.01% 1764
2024
Q1
$686K Buy
143,585
+12,905
+10% +$59.9K ﹤0.01% 2469
2023
Q4
$627K Buy
130,680
+6,538
+5% +$40K ﹤0.01% 2531
2023
Q3
$899K Buy
124,142
+834
+0.7% +$6.66K ﹤0.01% 2266
2023
Q2
$916K Buy
123,308
+25,235
+26% +$198K ﹤0.01% 2337
2023
Q1
$680K Buy
98,073
+16,055
+20% +$148K ﹤0.01% 2300
2022
Q4
$843K Sell
82,018
-11
-0% -$194 ﹤0.01% 2227
2022
Q3
$1.49M Buy
82,029
+2,099
+3% +$91K ﹤0.01% 1934
2022
Q2
$4.11M Buy
79,930
+7,678
+11% +$398K 0.01% 1349
2022
Q1
$5.32M Sell
72,252
-6,270
-8% -$559K 0.01% 1271
2021
Q4
$11.2M Buy
78,522
+4,251
+6% +$730K 0.01% 925
2021
Q3
$15.4M Sell
74,271
-973
-1% -$214K 0.02% 729
2021
Q2
$16M Sell
75,244
-21,870
-23% -$4.01M 0.02% 733
2021
Q1
$17.6M Sell
97,114
-4,384
-4% -$874K 0.02% 653
2020
Q4
$11.3M Buy
101,498
+8,428
+9% +$896K 0.02% 840
2020
Q3
$10.1M Sell
93,070
-14,639
-14% -$1.78M 0.02% 770
2020
Q2
$8.98M Buy
107,709
+58,613
+119% +$2.24M 0.02% 834
2020
Q1
$667K Buy
49,096
+15,998
+48% +$135K ﹤0.01% 2045
2019
Q4
$132K Sell
33,098
-330
-1% -$1.43K ﹤0.01% 2843
2019
Q3
$168K Buy
33,428
+3,118
+10% +$17.1K ﹤0.01% 2789
2019
Q2
$178K Buy
30,310
+4,107
+16% +$32.3K ﹤0.01% 2822
2019
Q1
$289K Sell
26,203
-508
-2% -$16K ﹤0.01% 2568
2018
Q4
$983K Buy
26,711
+8,138
+44% +$315K ﹤0.01% 2024
2018
Q3
$698K Sell
18,573
-219
-1% -$6.17K ﹤0.01% 2149
2018
Q2
$504K Buy
18,792
+3,484
+23% +$118K ﹤0.01% 2311
2018
Q1
$643K Buy
15,308
+468
+3% +$18.8K ﹤0.01% 2118
2017
Q4
$368K Sell
14,840
-2,665
-15% -$65K ﹤0.01% 2361
2017
Q3
$399K Buy
17,505
+157
+0.9% +$3.52K ﹤0.01% 2425
2017
Q2
$399K Buy
17,348
+1,170
+7% +$23K ﹤0.01% 2415
2017
Q1
$414K Buy
16,178
+562
+4% +$15.5K ﹤0.01% 2335
2016
Q4
$394K Buy
15,616
+1,031
+7% +$30.1K ﹤0.01% 2347
2016
Q3
$607K Buy
14,585
+99
+0.7% +$12.8K ﹤0.01% 2090
2016
Q2
$2.11M Buy
14,486
+743
+5% +$85.2K 0.01% 1304
2016
Q1
$1.42M Buy
13,743
+149
+1% +$16K ﹤0.01% 1594
2015
Q4
$2.28M Buy
13,594
+1,520
+13% +$234K 0.01% 1275
2015
Q3
$1.71M Buy
12,074
+428
+4% +$96K 0.01% 1415
2015
Q2
$2.6M Buy
11,646
+497
+4% +$87.4K 0.01% 1235
2015
Q1
$1.84M Buy
11,149
+2,084
+23% +$338K 0.01% 1452
2014
Q4
$1.07M Buy
9,065
+298
+3% +$31.1K ﹤0.01% 1756
2014
Q3
$731K Buy
8,767
+172
+2% +$15.5K ﹤0.01% 1979
2014
Q2
$794K Buy
8,595
+1,463
+21% +$129K ﹤0.01% 1984
2014
Q1
$646K Buy
7,132
+119
+2% +$13.3K ﹤0.01% 2051
2013
Q4
$718K Buy
7,013
+953
+16% +$67.3K ﹤0.01% 2028
2013
Q3
$383K Sell
6,060
-60
-1% -$3.38K ﹤0.01% 2377
2013
Q2
$251K Buy
+6,120
New +$265K ﹤0.01% 2799

Other funds holding NVAX

RhumbLine Advisers's NVAX Position: Q2 2026 in Review

RhumbLine Advisers increased its Novavax (NVAX) stake by 7.9% in Q2 2026, buying an estimated $135K and bringing the position to 204,665 shares worth $1.93M. The position accounts for ﹤0.01% of the portfolio, ranked #1956.

RhumbLine Advisers first reported a position in NVAX in Q2 2013 and has held it in 53 quarters since. The position peaked at $17.6M in Q1 2021. 266 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

  • RhumbLine Advisers held 204,665 shares of Novavax worth $1.93M as of Q2 2026.
  • RhumbLine Advisers bought 15,065 Novavax shares in Q2 2026, an estimated $135K.
  • Novavax made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1956 holding.
  • RhumbLine Advisers first reported a position in Novavax in Q2 2013 and has held it in 53 quarters since.
  • RhumbLine Advisers's Novavax position peaked at $17.6M in Q1 2021.
  • 266 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.